1-6 of 6
Julian R. Molina
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, Palaniappan Kulanthaivel, Celine Pitou, Lynette B. Mulle, Daphne L. Farrington, Edward M. Chan, Matthew P. Goetz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (5): 1095–1102.
https://doi.org/10.1158/1078-0432.CCR-15-1718
Published: 29 February 2016
View article titled, A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell-McGuinn, Julian R. Molina, Johanna Bendell, James Spicer, Eunice L. Kwak, Susan S. Pandya, Robert Millham, Gary Borzillo, Kristen J. Pierce, Lixin Han, Brett E. Houk, Jorge D. Gallo, Maria Alsina, Irene Braña, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1888–1895.
https://doi.org/10.1158/1078-0432.CCR-14-1306
Published: 14 April 2015
View article titled, First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Open the PDF for First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Karen Lewandowski, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Hank Lee, Stew Kroll, Howard A. Burris, III
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2997–3004.
https://doi.org/10.1158/1078-0432.CCR-10-3425
Published: 01 May 2011
View article titled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Open the PDF for Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

Julian R. Molina, Scott H. Kaufmann, Joel M. Reid, Stephen D. Rubin, Marina Gálvez-Peralta, Robert Friedman, Karen S. Flatten, Kevin M. Koch, Tona M. Gilmer, Robert J. Mullin, Roxanne C. Jewell, Sara J. Felten, Sumithra Mandrekar, Alex A. Adjei, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7900–7908.
https://doi.org/10.1158/1078-0432.CCR-08-0415
Published: 01 December 2008
View article titled, Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Open the PDF for Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data in another window
Includes: Supplementary data
Journal Articles

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel, Donghua Yin, Julian R. Molina, L. Rhoda Molife, Timothy A. Yap, M. Luisa Roberts, Amarnath Sharma, Antonio Gualberto, Alex A. Adjei, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5834–5840.
https://doi.org/10.1158/1078-0432.CCR-07-1118
Published: 01 October 2007
View article titled, Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors
Open the PDF for Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors in another window
Journal Articles

Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer

Alex A. Adjei, Julian R. Molina, Sumithra J. Mandrekar, Randolph Marks, Joel R. Reid, Gary Croghan, Lorelei J. Hanson, James R. Jett, Chenghua Xia, Chetan Lathia, Ronit Simantov
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2684–2691.
https://doi.org/10.1158/1078-0432.CCR-06-2889
Published: 01 May 2007
View article titled, Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer
Open the PDF for Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer in another window